High-Energy Collimator Is Preferable to Medium-Energy Collimator for Evaluating 223Ra Uptake in Bone Metastasis at 2 Weeks Postinjection

Akira Ichimura, Tadaki Nakahara, Yoshiki Owaki, Kiyotaka Nakajima, Masahiro Jinzaki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

An 80-year-old man with castration-resistant prostate cancer received Ra injection to treat bone metastases. Two weeks after the injection, the patient underwent static Ra scan of the chest with medium-energy and high-energy collimators for 30 minutes each. Images obtained with the 2 collimators showed that uptake in metastatic lesions was visually clearer and semiquantitatively higher with the high-energy collimator. The use of HE collimator for Ra imaging in the early phase has been reported, and the present case suggests that in the late phase HE collimator would also be preferable to medium-energy collimator in terms of lesion-based evaluation.

Original languageEnglish
Pages (from-to)71-72
Number of pages2
JournalClinical Nuclear Medicine
Volume43
Issue number1
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Neoplasm Metastasis
Bone and Bones
Injections
Castration
Prostatic Neoplasms
Thorax

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

High-Energy Collimator Is Preferable to Medium-Energy Collimator for Evaluating 223Ra Uptake in Bone Metastasis at 2 Weeks Postinjection. / Ichimura, Akira; Nakahara, Tadaki; Owaki, Yoshiki; Nakajima, Kiyotaka; Jinzaki, Masahiro.

In: Clinical Nuclear Medicine, Vol. 43, No. 1, 01.01.2018, p. 71-72.

Research output: Contribution to journalArticle

@article{d8e16a9d85c24186b2e6bdf78ab305f3,
title = "High-Energy Collimator Is Preferable to Medium-Energy Collimator for Evaluating 223Ra Uptake in Bone Metastasis at 2 Weeks Postinjection",
abstract = "An 80-year-old man with castration-resistant prostate cancer received Ra injection to treat bone metastases. Two weeks after the injection, the patient underwent static Ra scan of the chest with medium-energy and high-energy collimators for 30 minutes each. Images obtained with the 2 collimators showed that uptake in metastatic lesions was visually clearer and semiquantitatively higher with the high-energy collimator. The use of HE collimator for Ra imaging in the early phase has been reported, and the present case suggests that in the late phase HE collimator would also be preferable to medium-energy collimator in terms of lesion-based evaluation.",
author = "Akira Ichimura and Tadaki Nakahara and Yoshiki Owaki and Kiyotaka Nakajima and Masahiro Jinzaki",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/RLU.0000000000001909",
language = "English",
volume = "43",
pages = "71--72",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - High-Energy Collimator Is Preferable to Medium-Energy Collimator for Evaluating 223Ra Uptake in Bone Metastasis at 2 Weeks Postinjection

AU - Ichimura, Akira

AU - Nakahara, Tadaki

AU - Owaki, Yoshiki

AU - Nakajima, Kiyotaka

AU - Jinzaki, Masahiro

PY - 2018/1/1

Y1 - 2018/1/1

N2 - An 80-year-old man with castration-resistant prostate cancer received Ra injection to treat bone metastases. Two weeks after the injection, the patient underwent static Ra scan of the chest with medium-energy and high-energy collimators for 30 minutes each. Images obtained with the 2 collimators showed that uptake in metastatic lesions was visually clearer and semiquantitatively higher with the high-energy collimator. The use of HE collimator for Ra imaging in the early phase has been reported, and the present case suggests that in the late phase HE collimator would also be preferable to medium-energy collimator in terms of lesion-based evaluation.

AB - An 80-year-old man with castration-resistant prostate cancer received Ra injection to treat bone metastases. Two weeks after the injection, the patient underwent static Ra scan of the chest with medium-energy and high-energy collimators for 30 minutes each. Images obtained with the 2 collimators showed that uptake in metastatic lesions was visually clearer and semiquantitatively higher with the high-energy collimator. The use of HE collimator for Ra imaging in the early phase has been reported, and the present case suggests that in the late phase HE collimator would also be preferable to medium-energy collimator in terms of lesion-based evaluation.

UR - http://www.scopus.com/inward/record.url?scp=85048721394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048721394&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000001909

DO - 10.1097/RLU.0000000000001909

M3 - Article

C2 - 29166333

AN - SCOPUS:85048721394

VL - 43

SP - 71

EP - 72

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 1

ER -